Thymosin β4 Attenuates Early Diabetic Nephropathy in a Mouse Model of Type 2 Diabetes Mellitus

American Journal of Therapeutics

Volumn 22, Issue 2, 2015, Pages 141-146

  Zhu, Jian ^a,b   Su, Li Ping ^b   Zhou, Yue ^b   Ye, Lei ^b,c   Lee, Kok Onn ^b   Ma, Jian Hua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

diabetic nephropathy; thymosin 4; type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; NITROGEN; THYMOSIN BETA4; TRIACYLGLYCEROL; UREA; ANTIINFLAMMATORY AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; THYMOSIN; THYMOSIN BETA(4);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; EXPERIMENTAL DIABETES MELLITUS; GLOMERULUS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; KIDNEY STRUCTURE; MICROALBUMINURIA; MOUSE; MOUSE MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PRIORITY JOURNAL; RENAL PROTECTION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ANIMAL; C57BL MOUSE; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C57BL; THYMOSIN;

EID: 84925247133     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182785ecc     Document Type: Article

References (34)

1. Valk EJ, Bruijn JA, Bajema IM. Diabetic nephropathy in humans: pathologic diversity. Curr Opin Nephrol Hypertens. 2011;20:285-289.
2. Hovind P, Tarnow L, Rossing K, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care. 2003;26:1258-1264.
3. Yokoyama H, Okudaira M, Otani T, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 2000;58:302-311.
4. Ito T, Tanimoto M, Yamada K, et al. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology (Carlton). 2006; 11:29-35.
5. Choudhury D, Tuncel M, Levi M. Diabetic nephropathy - a multifaceted target of new therapies. Discov Med. 2010; 10:406-415.
6. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med. 2001;345:910-912.
7. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7:327-340.
8. Yang L, Brozovic S, Xu J, et al. Inflammatory gene expression in OVE26 diabetic kidney during the development of nephropathy. Nephron Exp Nephrol. 2011;119:e8-e20.
9. Tuttle KR. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol. 2005;16:1537-1538.
10. Utimura R, Fujihara CK, Mattar AL, et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 2003;63:209-216.
11. Zhang Y, Chen B, Hou XH, et al. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats. Chin Med J (Engl). 2007;120:988-995.
12. Karalliedde J, Gnudi L. Endothelial factors and diabetic nephropathy. Diabetes Care. 2011;34:S291-S296.
13. Nakagawa T, Tanabe K, Croker BP, et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol. 2011;7:36-44.
14. Sosne G, Qiu P, Goldstein AL, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24:2144-2151.
15. Crockford D, Turjman N, Allan C, et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189.
16. Hinkel R, Bock-Marquette I, Hatzopoulos AK, et al. Thymosin beta4: a key factor for protective effects of eEPCs in acute and chronic ischemia. Ann N Y Acad Sci. 2010; 1194:105-111.
17. Smart N, Risebro CA, Clark JE, et al. Thymosin beta4 facilitates epicardial neovascularization of the injured adult heart. Ann N Y Acad Sci. 2010;1194:97-104.
18. Young JD, Lawrence AJ, MacLean AG, et al. Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med. 1999;5:1424-1427.
19. Sosne G, Qiu P, Christopherson PL, et al. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84:663-669.
20. Ding DF, You N, Wu XM, et al. Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK. Am J Nephrol. 2010;31:363-374.
21. Matsusaka T, Xin J, Niwa S, et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol. 2005;16:1013-1023.
22. Iwatsuka H, Shino A, Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol Jpn. 1970;17: 23-35.
23. Okazaki M, Saito Y, Udaka Y, et al. Diabetic nephropathy in KK and KK-Ay mice. Exp Anim. 2002;51:191-196.
24. Cooper ME, El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ Res. 2010;107: 1403-1413.
25. Siebel AL, Fernandez AZ, El-Osta A. Glycemic memory associated epigenetic changes. Biochem Pharmacol. 2010; 80:1853-1859.
26. Ko GJ, Kang YS, Han SY, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant. 2008;23:2750-2760.
27. Zoja C, Corna D, Gagliardini E, et al. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol. 2010;299:F1203-F1211.
28. Chen KH, Hung CC, Hsu HH, et al. Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-beta/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats. Chem Biol Interact. 2011;190:45-53.
29. Qiu P, Wheater MK, Qiu Y, et al. Thymosin {beta}4 inhibits TNF-α-induced NF-{kappa}B activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J. 2011;25:1815-1826.
30. Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent. Clin Ophthalmol. 2007;1:201-207.
31. Mora CA, Baumann CA, Paino JE, et al. Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice. Int J Immunopharmacol. 1997;19:1-8.
32. Makino H, Okada S, Nagumo A, et al. Decreased circulating CD34+ cells are associated with progression of diabetic nephropathy. Diabet Med. 2009;26:171-173.
33. Dessapt C, Karalliedde J, Hernandez-Fuentes M, et al. Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care. 2010;33:875-877.
34. Qiu FY, Song XX, Zheng H, et al. Thymosin beta4 induces endothelial progenitor cell migration via PI3K/Akt/eNOS signal transduction pathway. J Cardiovasc Pharmacol. 2009; 53:209-214.